當(dāng)前位置:> 供求商機> NIBSC代理
[供應(yīng)]NIBSC代理 返回列表頁
貨物所在地:國外
更新時間:2024-11-18 09:28:37
有效期:2024年11月18日 -- 2025年11月18日
已獲點擊:924
聯(lián)系我時,請告知來自 化工儀器網(wǎng)
您好, 歡迎來到化工儀器網(wǎng)! 登錄| 免費注冊| 產(chǎn)品展廳| 收藏商鋪|
貨物所在地:國外
更新時間:2024-11-18 09:28:37
有效期:2024年11月18日 -- 2025年11月18日
已獲點擊:924
聯(lián)系我時,請告知來自 化工儀器網(wǎng)
北京百奧創(chuàng)新代理NIBSC在中國的業(yè)務(wù)。NIBSC代理,NIBSC代理,NIBSC華東代理,NIBSC華北代理,NIBSC華中代理,NIBSC華南代理、NIBSC代理
The National Institute for Biological Standards and Control (NIBSC) plays a major national and international role in assuring the quality of biological medicines through:
We play a key role in providing scientific advice and expertise to a large number of organisations, including:
Contributions from NIBSC scientists, as members of key decision-making bodies at both European and international level, feed into the development of national and international policies that help to ensure the safety and efficacy of biological medicines.
We serve a broad range of customers and stakeholders in the UK and abroad and have a worldwide reputation for independence, integrity and scientific excellence.
NIBSC代理,NIBSC代理
Biological reference materialsCentre for AIDS ReagentsCurrent influenza standardsQuality control reagentsResult Reporting System (RRS)CJD Resource CentreOrderingBiological standards price list
BiotherapeuticsDiagnosticsVaccinesCytokines and Growth Factors Endotoxin Haemostasis Immunogenicity Immunoglobulins and immune sera Protein Hormones and Endocrine Products Quality Control Reagent UK Stem Cell Bank Mouse Embryo Fibroblasts Allergen Anti-Toxins Blood borne pathogens Blood Transfusion and Transplantation Ebola Virus Genomic Reference Material Haematinics and Haemoglobin Haemostasis Human Papillomavirus Immunoglobulins and immune sera Miscellaneous Parasitology Parvovirus Protein Hormones and Endocrine Products Quality Control Reagent Zoonosis and livestock diseases Botulinum Clostridium Diphtheria Ebola Virus Enteric disease Haemophilus Influenzae type b (Hib) Human Papillomavirus Influenza JE/Dengue Malaria Meningococcal typing and ELISA reagents MMR Parasitology Pertussis Pneumococcal vaccines Polio Quality Control Reagent Staphylococcal Immune Sera Tetanus Tuberculosis Vaccinia Yellow Fever Zoonosis and livestock diseases Complete product list NIBSC
Product NumberDescription00/410 MAPREC assay of poliovirus type 1 (Sabin).* 480-A, 525-C DNA(1st International Reference Preparation)International Reference Preparation 00/416 Low Mutant Virus Reference for MAPREC assay of poliovirus type 1 (Sabin)(1st International Reference Preparation)International Reference Preparation 00/418 MAPREC assay of poliovirus type 1 (Sabin) (1st International Standard)WHO International Standard 00/422 High Mutant Virus Reference for MAPREC assay of poliovirus type 1 (Sabin)(1st International Reference Preparation)International Reference Preparation 00/440 Influenza Antiserum A/Singapore/1/57 (H2)Influenza Reagent 00/442 Influenza anti B/Yamanashi/166/98 SerumInfluenza Reagent 00/464 Streptokinase (3rd International Standard 2001)WHO International Standard 00/500 Botulinum Type A-E Antitoxin, Human SerumNon WHO Reference Material 00/530 Influenza Virus infectious B/Sichuan/379/99Influenza Reagent 00/542 Influenza anti- A/Chick/Scotland/59 (H5N1) Seru
產(chǎn)品列表
00/544 | Influenza Virus infectious B/Victoria/504/00 |
00/546 | Influenza Antigen B/Johannesburg/5/99 |
00/552 | Influenza Antigen A/Duck/Singapore-Q/F119-3/97 (H5N3) |
00/556 | Influenza anti-B/Johannesburg/5/99/ Serum |
00/562 | Hepatitis A Virus for Nucleic Acid Amplification Techniques(2nd International Standard) |
00/572 | Interferon Beta (Human, rDNA, Glycosylated) (3rd International standard) |
00/574 | Interferon Beta SER17 Mutein (Human, rDNA derived) |
00/576 | Interferon Beta (Human, Fibroblast-derived, Glycosylated) |
00/614 | Influenza virus infectious B/Guangdong/120/2000 |
007SP | Human Anti-Pneumococcal capsule Reference Serum (1st International Standard) |
01/412 | Anti-Meningococcal Immunotype L3,7,9 Monoclonal Antibody |
01/420 | Interleukin-17 (Human rDNA derived)(International Reference Reagent) |
01/424 | Vascular Endothelial Growth Factor, Human rDNA derived |
01/426 | Meningococcal group Y polysaccharide |
01/428 | Meningococcal serogroup W polysaccharide |
01/450 | Influenza anti B/Guangdong/120/2000 Serum |
01/452 | Influenza anti A/Panama/2007/99 (H3N2) HA serum |
01/506 | Botulinum type F antitoxin, equine |
01/508 | Botulinum type C antitoxin, equine |
01/510 | Botulinum Antitoxin Equine Type D |
01/512 | Botulinum type G antitoxin, equine |
01/514 | Anti-Meningococcal Serosubtype P1.7 Monoclonal Antibody |
01/528 | Oral Poliovaccine Sabin Type 1 reference strain [LS-c, 2ab strain] (Panel of 5 ampoules) |
01/532 | Oral Poliovaccine Sabin Type 3 reference strain (Panel of 5 ampoules) |
01/538 | Anti-Meningococcal Serosubtype P1.16 mAb |
01/546 | Influenza Antigen B/Guangdong/120/2000 |
01/572 | Anti-D Immunoglobulin(2nd International Standard) |
01/580 | Thrombin, human(2nd International Standard) |
01/600 | Anti-Toxoplasma IgG, Human(International Standard) |
01/602 | Anti-Parvovirus B19, plasma, human(2nd International Standard) |
01/612 | Influenza Virus infectious B/Hawaii/10/01 |
01/614 | Influenza Antigen A/New Caledonia/20/99 |
02/102 | Influenza anti A/Panama/2007/99 Serum |
02/144 | Anti-Meningococcal Serosubtype P1.15 mAb |
02/148 | Anti-Meningococcal Serosubtype P1.4 mAb |
02/168 | Prekallikrein Activator (PKA), Human(2nd International Standard) |
02/178 | Anti-Meningococcal Serosubtype P1.2 mAb |
02/180 | Anti-Meningococcal Serotype P2.2a mAb |
02/182 | Anti-Japanese Encephalitis Virus Plasma, Human |
02/184 | Anti-Japanese Encephalitis (Anti-JE) Virus Negative Control Plasma, Human |
02/206 | Factor XIII Plasma, Human (1st International Standard) |
02/210 | HIV (antibody), 1st International Reference Panel |
02/226 | IVIG negative control for use with IVIG + anti-D(International Reference Reagent) |
02/228 | IVIG + anti-D for use with negative control IVIG(International Reference Reagent) |
02/230 | Biotinylated Brad-5 (Bio-Brad-5) |
02/232 | Tetanus Toxoid (Non-Adsorbed) |
02/254 | Insulin-like Growth Factor-1, recombinant, human, for immunoassay(1st International Standard) |
02/262 | Influenza Virus infectious B/Brisbane/32/2002 |
02/286 | Vascular Endothelial Growth Factor 165 (VEGF165)(recDNA, human sequence)(International Reference Reagent) |
02/294 | Influenza Antiserum A/chick/Italy/1347/99 (H7N1) |
02/308 | Anti-Meningococcal Serotype P3.4 mAb |
02/310 | Anti-Meningococcal Serotype P3.15 mAb |
02/318 | Botulinum Antitoxin Equine Type E |
02/320 | Anti-Meningococcal Serosubtype P1.3 mAb |
02/336 | Influenza Antigen A/New Caledonia/20/99 |
02/338 | Influenza anti A/Panama/2007/99 Serum |
02/342 | Protein C Plasma, Human(2nd International Standard) |
03/104-018 | HTLV-1 (antibody) Monitor Sample |
03/110 | Influenza anti B/Shangdong/9/97 Serum |
03/114 | Anti-Meningococcal Serosubtype P1.1 mAb |
03/116 | Blood Coagulation Factor V, Plasma Human (1st International Standard) |
03/124 | Thrombopoietin ( Human rDNA derived) |
03/142 | Anti-Meningococcal Serosubtype P1.14 mAb |
03/148 | Keratinocyte growth factor (KGF, FGF-7)(24-163)(1st International Reference Reagent) |
03/150 | Keratinocyte Growth Factor (KGF,FGF-7)(1st International Reference Reagent) |
03/152 | Anti-HPA-1a (International Standard) |
03/164 | Anti-B minimum potency reference preparation(International Standard) |
03/178 | Vitamin B12, Serum Folate and holoTC (International standard) |
03/182 | Anti-Meningococcal Serotype P3.21 mAb |
03/188 | Anti-A minimum potency reference preparation(International Standard) |
03/190 | Anti-HPA-3a(minimum potency)(International Reference Reagent) |
03/192 | Thyroid-Stimulating Hormone, Recombinant, Human, for Bioassay (1st International standard) |
03/198 | Influenza Virus infectious A/Kumamoto/102/02 |
03/200 | Interleukin - 18 (Human rDNA derived)(International Reference Reagent) |
03/210 | Anti-Meningiococcal Serosubtype P1.6 mAb |
03/212 | Influenza anti A/Wyoming/03/03 Serum |
03/220 | Influenza Antigen A/Wyoming/03/03 |
03/224 | Anti-Meningococcal Serosubtype P1.10 mAb |
03/226 | Anti-Meningococcal Serosubtype P1.5 mAb |
03/228 | Protein S, Plasma, Human(2nd International Standard) |
03/236 | Anti-Meningococcal Serosubtype P1.13 mAb |
03/242 | Influenza anti A/Puerto Rico/8/34 (H1N1) HA Serum |
03/244 | Influenza Antiserum A/chick/Germany/N/49 |
03/258 | Influenza Antigen A/New Caledonia/20/99 (IVR-116) |
03/262 | Hepatitis B Surface Antigen subtype adw2, genotype A (International Reference Panel) |
04/122 | Anti-Meningococcal Serosubtype P1.12 mAb |
04/132 | IVIG + Anti-D for use with negative control IVIG |
04/140 | IVIG Negative Control for use with IVIG & Anti-D |
04/150 | Tetanus Toxoid For Flocculation Test(2nd International Standard) |
04/160 | Influenza Virus infectious NYMC X-147 |
04/166 | TNF-related Apoptosis-Inducing Ligand (trail), Human, rDNA-derived(1st International Reference Reagent) |
04/170 | Influenza Virus infectious A/Wellington/1/2004 |
04/172 | Influenza Virus infectious IVR-139 |
04/176 | Plasmodium falciparum DNA for NAT Assays(1st International Standard) |
04/198 | Anti-Meningococcal Serotype P3.1 mAb |
04/200 | Parathyroid hormone 1-34 ,Recombinant, Human(International Standard) |
04/202 | Influenza Antigen B/ Jiangsu/10/2003 |
04/214 | Influenza Antiserum A/Viet Nam/1194/04 (H5N1) |
04/224 | Factor V Leiden, Human gDNA, 1st International Genetic Reference Panel 2004 |
04/228 | Influenza anti B/ Neuraminidase Serum |
04/242 | Influenza anti B/Jiangsu/10/2003 HA Serum |
04/246 | Anti-Meningococcal Serogroup W-135 mAb |
04/248 | Anti-Meningococcal Serosubtype P1.19 mAb |
04/252 | Protein C Concentrate, Human(1st International Standard) |
04/260 | Influenza anti A/New Caledonia/20/99 HA Serum |
04/262 | Influenza anti A/New York/55/2004 HA Serum |
04/264 | Influenza Antigen A/New York/55/2004 (H3N2) (NYMC X-157) |
05/102 | Influenza Virus infectious NYMC BX-7 |
05/106 | Anti-HPA-1a minimum potency reagent(2nd International Reference reagent) |
05/110 | Influenza Virus infectious A/California/7/2004 |
05/112 | Low Molecular Weight Heparin for Molecular Weight Calibration (2nd International Standard). |
05/122 | Syphilitic plasma IgG (human)(1st International Standard) |
05/130 | Prothrombin Mutation G20210A, Human gDNA(1st International Genetic Reference Panel 2005) |
05/134 | Anti-human papillomavirus type 16 serum (1st International Standard) |
05/138 | Influenza Virus infectious B/Shanghai/361/2002 |
05/162 | Alpha-1-Antitrypsin, plasma derived(1st International standard) |
05/190 | Anti Meningococcal Serosubtype P1.9 Monoclonal Antibody |
05/192 | Anti Meningococcal Serotype P2.2b Monoclonal Antibody |
05/234 | Influenza Antigen A/Hiroshima/52/2005 (H3N2) (IVR-142) |
05/236 | Influenza anti A/Wisconsin/67/2005 Serum |
05/242 | IVIG, Anti-D and Negative Control Panel |
05/252 | Influenza anti B Neuraminidase Serum |
06/108 | Influenza Virus infectious IVR-116 |
06/114 | Influenza Virus Infectious A/PR/8/34 |
06/124 | Monoclonal Antibody for Serotyping Bordela pertussis Fimbrial Antigen 2 (1st International Standard) |
06/128 | Monoclonal Antibody for Serotyping Bordela pertussis Fimbrial Antigen 3 (1st International Standard) |
06/140 | Pertussis Antiserum(human)1st IS-WHO international Standard. |
06/142 | Pertussis Antiserum (Human) 1st WHO Reference Reagent |
06/164 | Influenza Virus infectious 1 VR-142 |
06/166 | Antithrombin Concentrate, Human (3rd International Standard) |
06/170 | Influenza Antigen A/New Caledonia/20/99 |
06/192 | Influenza anti A/turkey/Turkey/1/05 (NIBRG-23) HA serum(sheepSH465 & SH466) |
06/202 | Human Papillomavirus (HPV) Type 16 DNA (1st International Standard) |
06/206 | Human Papillomavirus (HPV) Type 18 DNA (1st International Standard) |
06/242 | Influenza Virus Infectious NYMC X-161B (A/Wisconsin/67/2005 HGR) |
07/102 | Influenza Antigen A/Solomon Islands/3/2006 (H1N1)(IVR-145) |
07/104 | Influenza anti A/Solomon Islands/3/2006 (H1N1) (IVR-145) HA Serum |
07/112 | Influenza Antigen A/turkey/Turkey/1/2005 (H5N1) NIBRG-23 |
07/132 | Influenza Virus infectious B/Malaysia/2506/2004 |
07/144 | Influenza Virus infectious IVR-145, |
07/146 | Influenza anti A/HongKong/1073/99 like (H9) HA Serum (sheep) |
07/148 | Influenza anti A/Vietnam/1194/04 (H5N1) HA Serum |
07/150 | Human Plasma Anti-Influenza H5N1 (1st International Standard) |
07/164 | Anti-hepatitis B surface antigen(Anti-HBs) immunoglobulin (2nd International Standard) |
07/184 | Influenza anti B/Malaysia/2506/2004-HA Serum |
07/202 | Recombinant soluble transferrin receptor (rsTfR)(1st WHO Reference Reagent) |
07/204 | Influenza Virus Infectious NIBRG-60 VE2 25820 |
07/214 | Positive Control for use in flow cytometry cross matching (FCXM) |
07/216 | Diphtheria Toxoid (Adsorbed) (4th International Standard) |
07/222 | RhD/SRY Plasma DNA sensitivity standard (1st International Reference Reagent) |
07/226 | Influenza Virus Infectious A/New Caledonia/20/99 |
07/228 | Blood Coagulation Factor VIIa, Concentrate, Human, 2nd International Standard” |
07/246 | Influenza Virus Infectious IVR-147 |
07/268 | Influenza Virus Infectious B/Brisbane/3/2007 |
07/270 | BCG Vaccine of Danish 1331 sub-strain (1st WHO Reference Reagent) |
07/272 | BCG Vaccine of Tokyo 172 sub-strain(1st WHO Reference Reagent) |
07/274 | BCG Vaccine of Russian BCG-I sub-strain(1st WHO Reference Reagent) |
07/278 | Influenza anti A/mallard/Netherlands/12/2000 (H7) HA serum (NIBRG-60) (sheep SH474 AND SH475) |
07/286-014 | 0.05 IU HBsAg Monitor Sample |
07/288-016 | Hepatitis B Surface Antigen British Working Standard 0.2 IU/ml |
07/290 | Influenza Antigen A/Anhui/1/05 (H5N1) IBCDC-RG-6 |
07/296-006 | Influenza Virus (A/Christchurch/1/2003, H1N1) for Nucleic Acid Amplification Techniques |
07/298-006 | Influenza Virus (A/Wyoming/3/2003, H3N2) for Nucleic Acid Amplification Techniques |
07/300-005 | Influenza Virus (B/Jiangsu/10/2003) for Nucleic Acid Amplification Techniques |
07/304 | Anti-D for assuring operator and test performance |
07/306 | Anti-A and anti-B in IVIG: Positive control for haemagglutination tests (International Reference Reagent) |
07/316 | Blood Coagulation Factor VIII and Von Willebrand Factor in Plasma (6th I.S.) |
07/318 | Meningococcal Group C Polysaccharide |
07/328 | Unfractionated Heparin (6th I.S.) |
07/336 | Influenza Antigen A/mallard/Netherlands/12/00(H7N3) NIBRG-60 |
07/338 | Influenza antiserum A/Anhui/1/05 (H5) |
07/348 | Influenza Virus infectious NYMC X-171B |
07/350 | Blood Coagulation Factor VIII Concentrate (8th I.S.) |
07/358 | Influenza Virus infectious NIB-50 |
07/362 | Influenza Virus infectious IVR-149 |
07/364 | Chorionic Gonadotrophin, (5th International Standard) |
07/B498-18 | QCRHBclgMQC1-IgM Anti-HBc Quality Control Serum: Sample1 |
08/100 | Influenza Antigen A/Brisbane/59/2007 (IVR-148) (H1N1) |
08/108 | Influenza Virus Infectious NIBRG-91 |
08/118-005 | Parainfluenza Virus serotype 3 for Nucleic Acid Amplification Techniques |
08/120-006 | Human Respiratory syncytial virus A2 for Nucleic Acid Amplification Techniques |
08/126 | Influenza Anti N1 Neuraminidase Serum SH485 |
08/138 | Influenza Virus Infectious B/Florida/4/2006 |
08/140 | Influenza Antigen B/Florida/4/2006 |
08/142 | Influenza antiserum A/Anhui/1/05 (H5) |
08/148 | Positive control for Luminex based anti-HLA Class II serology |
08/150 | HIV-2 RNA(1st International Standard) |
08/154 | Influenza Virus Infectious NIBRG-12 |
08/156 | Influenza Virus Infectious NIBRG-23 30060 VE3 |
08/158 | Fragile X Syndrome gDNA (1st International Genetic Reference Panel) |
08/160 | Haemophilia A, Intron-22 inversion, gDNA, (1st International Genetic Reference Panel) |
08/176-005 | Parainfluenza Virus serotype 1 for Nucleic Acid Amplification Techniques |
08/178-005 | Parainfluenza Virus serotype 2 for Nucleic Acid Amplification Techniques |
08/180-005 | Parainfluenza virus serotype 4 for Nucleic Acid Amplification Techniques |
08/184 | Influenza Antigen B/Malaysia/2506/2004 |
08/202 | Influenza anti A/chick/Hong Kong/G9/1997/(H9) HA serum (NIBRG-94)(H9N1) |
08/204 | Thyroid Stimulating Antibody (2nd I.S.) |
08/208 | Influenza Antigen Hong Kong/1073/99 (H9N2) |
08/210 | Influenza anti A/Cambodia/R0405050/2007 (H5) HA serum (NIBRG-86) |
08/214 | Meningococcal Serogroup C polysaccharide (1st International Standard) |
08/216 | Influenza Antigen A/Cambodia/RO405050/2007 (H5N1) |
08/218 | Tetanus Toxoid Adsorbed (4th International Standard) |
08/228 | Influenza Antigen A/chick/Hong Kong/G9/1997 (H9N2) NIBRG-91 |
08/230 | Streptodornase (2nd International Standard) |
08/246 | Influenza anti A/Brisbane/10/2007- like HA serum |
08/256 | C1- Inhibitor, Concentrate (1st International Standard) |
08/258 | Antithrombin, Plasma (3rd International Standard) |
08/262 | C1 Inhibitor (Plasma)(1st International Standard) |
08/266 | Sex Hormone Binding Globulin.(2nd International Standard) |
08/268 | Influenza Antigen A/mallard/England/727/2006 (H2N3)NIBRG-107 |
08/278 | Influenza Antigen A/Brisbane/10/2007-like (Prepared from A/Uruguay/716/2007 (NYMC X-175C)) |
08/282 | Follicle-Stimulating Hormone, human, recombinant, for bioassay (2nd International Standard) |
08/298 | Influenza Virus Infectious B/Brisbane/33/2008 30720 E5 |
08/300 | Influenza Virus Infectious IVR-148 |
08/304 | Influenza virus infectious NYMC X-175C |
08/318-007 | Human Norovirus GI Working Reagent for Nucleic Acid Amplification Testing |
08/320-007 | Human Metapneumovirus Working Reagent for Nucleic Acid Amplification Testing |
08/322-006 | Human Parechovirus Working Reagent for Nucleic Acid Amplification Testing |
08/324-005 | Human Rhinovirus Genogroup A Working Reagent for Nucleic Acid Amplification Testing |
08/356 | Influenza antiserum A/Japan/305/57 (H2) |
08/362 | Influenza Antigen A/New York/107/2003 (H7N2)NIBRG-109 |
09/100 | Influenza anti A/mallard/England/727/2006 (N3) NA serum (NIBRG-107) (Sheep SH503) |
09/110 | Parvovirus B19 DNA Nucleic Acid Amplification Technology(NAT) based assays Genotype Panel(1st International Standard) |
09/112 | Negative Control for use in flow cytometry cross matching (FCXM) and anti-HLA serology |
09/130 | Influenza Virus Infectious NIBRG-122 |
09/132-004 | Human Coronavirus 229E Working Reagent for Nucleic Acid Amplification Testing |
09/136 | Granulocyte Colony Stimulating Factor (Human, rDNA Derived)(2nd International Standard) |
09/138 | Genetic Reference Panel, for the quantitation of BCR-ABL translocation by RQ-PCR (1st I.S.) |
09/140 | Prader Willi & Angelman Syndromes, Human gDNA,(1st International Genetic Reference Panel) |
09/148 | Influenza anti A/New York/107/2003 (H7) HA serum (Sheep SH504 and SH505) |
09/154 | Clostridium sordellii (Gas-gangrene) Antitoxin, Equine,(1st International standard) |
09/162 | Human Cytomegalovirus (HCMV) for Nucleic Acid Amplification Techniques (1st International Standard) |
09/170 | Anti-Meningococcal factor H binding protein variant 1 (JAR4) monoclonal antibody |
09/172 | Blood coagulation Factors II, VII, IX, X Plasma (4th International Standard 2010) |
09/174 | Influenza Antigen A/California/7/09 (H1N1)v (NYMCX-179A)(Cell Derived) |
09/182 | VWF Factor Concentrate (2nd International Standard) |
09/184 | Influenza Antigen A/Vietnam/1194/2004 (H5N1) NIBRG-14 |
09/186 | Chagas (anti-Trypanosoma cruzi II) antibody in human plasma(1st International Standard) |
09/188 | Chagas (anti-Trypanosoma cruzi I) antibody in Human Plasma (1st International Standard) |
09/196 | Influenza Antigen A/California/7/09 (H1N1)v (NIBRG-121xp) (Egg Derived) |
09/222 | Human anti-Haemophilus influenzae b reference serum |
09/234 | Transforming Growth Factor-BETA 3 (Human, rDNA derived TGF-ß 3) (1st International Standard) |
09/236 | Influenza Virus Infectious IVR-153 |
09/242 | Fibrinogen Concentrate (B)(2nd International Standard) |
09/260 | Epstein-Barr Virus for Nucleic Acid Amplification Techniques(1st International Standard) |
09/264 | Fibrinogen Plasma (D)(3rd International Standard) |
09/266 | GLIAL CELL-DERIVED NEUROTROPHIC FACTOR (GDNF), human, rDNA-derived |
09/268 | Influenza Virus Infectious NIBRG-121xp |
09/272 | Placental growth factor Ala 21 - Arg 149, human, rDNA-derived (PlGF, PlGF-1) |
09/274 | Influenza Virus Infectious NYMC X-185 |
09/280 | Influenza Virus Infectious NIB-64 |
09/284 | Anti-Human Neutrophil Antibody 1a WHO Reference Reagent |
09/296 | Pro-Insulin, human (1st International Standard) |
09/304 | Influenza Virus Infectious IVR-155 |
09/306 | Influenza Virus Infectious NIBRG-147 |
09/308 | Influenza Serology Antigen Reagent X-179A (H1N1pdm) for HI Assay |
09/310 | Influenza Antigen A/Wisconsin/15/09 (H3N2) (NYMCX-183) |
09/316 | Influenza Anti B Neuraminidase Serum (B/Florida/4/2006) |
09/B584-15 | QCRTHAVQC1-Total Anti-HAV Quality Control Serum: Sample1 |
10/104 | Reteplase Reference Material |
10/120 | Influenza Anti A/Brisbane/59/2007 (IVR 148)(H1N1) HA serum |
10/128 | Diphtheria Polyclonal Antibody |
10/130 | Diphtheria Monoclonal Antibody |
10/132 | Tetanus Polyclonal Antibody |
10/134 | Tetanus Monoclonal Antibody |
10/136-001 | HLA-DRB1 Genotyping Reference Panel |
10/140 | Anti-human papillomavirus[HPV] 18 serum (1st International Standard) |
10/142 | Negative control for Luminex based anti-HLA serology |
10/164 | Oral Poliovaccine Sabin Type 1 reference strain [LS-c, 2ab strain]. |
10/168 | Oral Poliovaccine Sabin Type 3 reference |
10/176 | Interleukin-29 (Interferon Lamda 1) |
10/178 | Endotoxin (3rd International Standard) |
10/188 | Factor VIII Concentrate (13th British Standard). |
10/198 | Anti-malaria (Plasmodium falciparum) human serum(1st International Reference Reagent) |
10/202 | Influenza antibody (Human) to A/California/7/2009 'like' (H1N1v) virus (2nd International Standard) |
10/214 | Influenza Anti N2 Neuraminidase Serum SH395 & SH396 |
10/218 | Influenza Anti A/California/7/2009 (N1) NA Serum |
10/226 | Influenza Virus Infectious IVR-158 |
10/232 | Genomic DNA for blood group genotyping RBC1(AR1R1)(International Reference Reagent) |
10/234 | Genomic DNA for blood group genotyping RBC12 (ODpsi)(International Reference Reagent) |
10/236 | Genomic DNA for blood group genotyping RBC4(OR1R2)(International Reference Reagent) |
10/238 | Genomic DNA for blood group genotyping RBC5(Brr)(International Reference Reagent) |
10/242 | Toxoplasma gondii DNA Nucleic Acid Amplification Techniques(1st International Standard) |
10/252 | Factor VII Concentrate(2nd International Standard) |
10/258 | Influenza Antigen A/California/7/2009-like(NIB-74) |
10/262 | Diphtheria Antitoxin Human IgG(1st International Standard) |
10/266 | 4th WHO International Standard for HBV DNA for NAT |
10/272 | BCG vaccine of Moreau-RJ sub-strain(1st International Reference Reagent) |
10/280 | Anti-HLA Control |
10/286 | Follicle Stimulating Hormone, Luteinizing Hormone human, urinary for bioassay(5th International Standard) |
10/B596-10 | QCRHSV1QC1-Anti-HSV1 Quality Control Serum: Sample1 |
1050 | IPV ELISA MAbs Type 1, 2 and 3 (Type 2; No: 1050) |
11/106 | Influenza Virus infectious A/Perth/16/2009 |
11/108 | Influenza Virus infectious NYMC X-187 |
11/126 | Factors II and X Concentrate (4th International standard) |
11/130 | Influenza Virus Infectious NIBRG-14 |
11/134 | Influenza Antigen A/California/7/2009 (H1N1) Like (A/Brisbane/10/2010- cell derived) |
11/170 | Erythropoietin, recombinant, for Bioassay (3rd International Standard) |
11/176 | (3rd International Standard) Low Molecular Weight Heparin |
11/184 | High Molecular Weight Urokinase(2nd International Standard) |
11/206 | Influenza anti-A/Perth/16/2009 HA Serum |
11/210 | Anti-human CD4 FITC conjugated 0.5ml |
11/214 | Blood Group Genotyping Reference Panel ((International Reference Reagent) |
11/216 | Chagas Antibody Reference Panel ( 1st International Standard) |
11/218-001 | MLH1/MSH2 Exon Copy Number Reference Panel |
11/222 | Influenza Virus Infectious NIB-79 |
11/226 | Influenza Virus Infectious A/Victoria/361/2011 |
11/232 | Influenza Virus Infectious B/Texas/6/2011 |
11/234 | Immunoglobulin E(IgE) human serum (3rd International Standard) |
11/242-001 | Viral Multiplex Reference |
11/244 | Influenza Virus Infectiious NYMC BX-49 |
11/B604-02 | QCRFLUAH5QC1 Influenza H5 PC1 |
11/B606-07 | QCRNEGQC1-Negative Quality Control Serum: Sample1 |
11/B608-03 | QCRHIV1QC1-Anti-HIV1:Quality Control Serum: Sample1 |
12/100 | Influenza Virus Infectious NYMC X-217 |
12/104 | International Standard for IPV 12/104 (3rd International Standard) |
12/106 | Influenza Antigen B/Hubei-Wujiagang/158/2009 (NYMCBX-39) |
12/110 | Influenza Antigen B/Wisconsin/1/2010 (cell derived) |
12/112 | Influenza Antigen A/Victoria/210/2009 (H3N2) (NYMCX-187) |
12/114 | Influenza Antigen A/Victoria/361/2011 (H3N2) (IVR-165) |
12/116 | Influenza anti-A/Victoria/361/2011-like HA serum |
12/118 | Influenza anti-B/Wisconsin/1/2010-like HA serum |
12/122 | Influenza virus infectious A/turkey/Italy/3889/1999 |
12/154 | Tumour Necrosis Factor alpha (human rDNA derived)(3rd International Standard) |
12/176 | Methylated Human Serum Albumin (mHSA) |
12/188 | Pegylated Granulocyte Colony Stimulating Factor (Human, rDNA derived) (International Standard) |
12/198 | Influenza virus infectious B/Wisconsin/1/2010 34490 E5 |
12/202 | Influenza virus infectious NYMC BX-39 |
12/204 | Influenza Virus infectious IVR-165 |
12/208 | Parvovirus B19 (3rd International Standard) |
12/224 | HIV-1 NAT subtypes (Main)(2nd International Reference Panel Preparation) |
12/226 | HBsAg (HBV genotype B4, HBsAg subtypes ayw1/adw2)(3rd International Standard) |
12/252 | ADAMTS 13 Plasma (1st International Standard) |
12/282 | Diphtheria Toxin 1Lf/ml |
12/284 | Anti-meningococcal serogroup Y monoclonal antibody |
12/290 | Influenza Virus Infectious B/Brisbane/36/2012 |
12/294 | Influenza Virus Infectious NYMC BX-51C |
12/298 | Influenza Virus Infectious A/Texas/50/2012 |
12/306 | Haemophilus Influenzae Polysaccharide Polyribosyl Ribitol Phosphate (PRP)(2nd International Standard) |
12/B611-03 | Anti-VZV Quality control serum: Sample 1 QCRVZV IgM QC1 |
12/B612-05 | QCRRUBIgMQC1-Anti-Rubella IgM Quality Control Serum: Sample 1 |
12/B613-06 | QCRRUBQC2-Anti-Rubella: Quality Control Serum: Sample 2 |
13/100 | Activated Blood Coagulation Factor XI (FXIa), Human (1st International Standard) |
13/106 | Influenza Antigen B/Massachusetts/02/2012 |
13/108 | Anti-Meningococcal serogroup B monoclonal antibody |
13/112 | Influenza Antigen A/Texas/50/2012 (NYMC X-223) |
13/116 | Influenza Antigen A/Texas/50/2012 (NYMC X-223A) |
13/122 | Erythropoietin Antibody Reference Panel Negative Control Antibody (1st WHO Reference Panel) |
13/126 | Influenza anti-B/Brisbane/60/2008-like HA serum |
13/132 | Antibodies, Human, to Toxoplasma gondii (4th International Standard). |
13/134 | Influenza Antigen B/Massachusetts/02/2012 (Egg derived) |
13/146 | C-Peptide, Human (1st International Standard). |
13/152 | Influenza Antigen B/Massachusetts/02/2012 (cell derived) |
13/162 | Influenza Antigen A/Texas/50/2012 (NYMC X-223A) (Cell derived) |
13/164 | Influenza Antigen A/California/7/2009 (H1N1pdm)(NYMC X-179A) |
13/166 | Influenza anti-A/Anhui/1/2013 (N9) NA Serum |
13/168-002 | Human Measles Mvi/Moscow Rus/1988 Genotype A Virus for Nucleic Acid Amplification Techniques |
13/172 | Lupus Anticoagulant (1st International Reference Panel) |
13/176 | Influenza Virus Infectious NIBRG-88 |
13/178 | Influenza Anti-A/Texas/50/2012-like HA Serum |
13/182 | Influenza Anti-B/Massachusetts/02/2012-like HA Serum |
13/198 | Influenza Virus Infectious NYMC X-181 |
13/200 | Influenza Virus Infectious NIB-74 |
13/202 | Influenza Virus Infectious NIB-74xp |
13/204 | TNF Rec II- FC Fusion protein (1st International Standard) |
13/206 | Plasmin (4th International Standard) |
13/212 | Diphtheria Toxoid for use in Flocculation Test (3rd International Standard) |
13/214 | HIV-1 Circulating Recombinant Forms RNA (1st International Reference Panel) |
13/216 | Anti-meningococcal factor H binding protein variant 1 (JAR5) monoclonal |
13/218 | Polio Anti Sabin type 1 (inactivated) Serum |
13/220 | Polio Anti Sabin type 2 (inactivated) serum |
13/222 | Polio Anti Sabin type 3 (inactivated) serum |
13/224 | Influenza virus Infectious NIB-85. 36210 E5 |
13/228 | Influenza Virus Infectious. A/Almaty/2958/2013. 35790 E4 |
13/234 | Influenza antigen B/Brisbane/60/08 |
13/238 | Anti-EV71 serum LOW (WHO International Reference Reagent) |
13/242 | FEIBA Concentrate 2nd NIBSC Working Reference Standard |
13/246 | Meningococcal serogroup A polysaccharide (1st WHO International Standard). |
13/248 | Influenza virus infectious NIBRG-267 |
13/250 | Influenza Virus Infectious NIBRG-268 |
13/252 | Influenza virus infectious NYMC X-223A |
13/256 | Influenza virus infectious. NYMC x-233 |
13/258 | Influenza virus infectious NYMC X-233A |
13/264 | Influenza Virus Infectious NYMC X-223 |
13/B629-05 | QCRHBeQC1-Anti-HBe Quality Control Serum: sample1 |
13/B631-05 | QCRHBsGQC1-HBsAg Quality Control Serum: Sample1 |
13/B634-04 | QCRHAVIgMQC2 IgM Anti-HAV Quality Control Serum: Sample2 |
13/B636-04 | QCRHIV1QC2- Anti-HIV 1: Quality Control Serum: Sample 2 |
13/B640-02 | QCRHIV1QC5 - Anti-HIV-1 Quality Control Reagent Sample 5 |
13/B642-06 | QCRHSV2QC1-Anti-HSV2 Quality Control Serum: Sample 1 |
13/B644-03 | QCRHIV1QC3-Anti-HIV1:Quality Control Serum:Sample 3 |
13/B650-02 | QCRCMVQC1- Anti CMV: Quality Control Serum: Sample 1 |
14/106 | Influenza virus infectious. NYMC BX-51B |
14/114 | JC Virus (JCV) DNA (1st International Standard) |
14/116 | Influenza virus infectious NYMC X-179A |
14/118 | Influenza virus infectious B/Massachusetts/2/2012 |
14/140 | 1st International Standard for Anti EV71 Serum Human |
14/144 | Influenza anti-N2 Neuraminidase serum (A/Victoria/361/2011) |
14/146 | Influenza Antigen B/Brisbane/60/2008 (NYMCBX-35)(Cell Derived) |
14/148 | Human Blood Factor IX Concentrate (5th International Standard). |
14/150 | Hepatitis C virus (HCV) For nucleic acid amplification techniques (5th International standard 2015) |
14/156 | Meningococcal group X polysaccharide (1st WHO International Standard) |
14/160 | High titre anti-A in IVIG working reference reagent |
14/174 | Botulinum Type A Antitoxin, Equine |
14/198-003 | HBV,HCV,HIV Multiplex |
14/200 | Influenza Antigen A/Puerto Rico/8/34 (HINI) |
14/204 | Influenza Virus Infectious B/Brisbane/9/2014 |
14/206 | Influenza virus infectious NYMC X-247 |
14/212 | BK Virus (BKV)(1st International Standard) |
14/224 | Influenza virus infectious. A/Switzerland/9715293/2013 |
14/226 | Influenza Virus Infectious A/South Australia/55/2014 |
14/228 | Influenza Virus Infectious A/Stockholm/6/2014 |
14/230 | Influenza Virus Infectious. A/Norway/466/2014 |
14/232 | Influenza Virus Infectious IVR-175 |
14/240-005 | British Working Standard for Anti-HCV |
14/242-003 | Anti-HCV (1 in 8 dilution)(British Working Standard) |
14/246 | Influenza Virus Infectious NIBRG-301 |
14/254 | Influenza Antigen A/Switzerland/9715293/2013 (NIB88) |
14/274 | Influenza Antigen B/Brisbane/9/2014 (Egg Derived) |
14/290 | 4th HCV RNA Genotype Panel for Nucleic Acid Amplification |
14/300 | High titre anti-A and anti-B in serum (WHO Reference Reagent). |
14/306 | Influenza Virus Infectious NYMC X-243 40180 E13 |
14/308 | Influenza Virus Infectious IVR-178 40200 E7 |
14/312 | Influenza Virus Infectious B/Phuket/3073/2013 |
14/314 | Influenza Virus Infectious NIB-88 |
14/320 | Influenza Virus Infectious B/Utah/9/2014 |
14/322 | Influenza Virus Infectious NIB-91 |
14/B651-02 | QCRTHBcQC2-Total Anti-HBc Quality Control Serum: Sample2 |
14/B653-01 | QCRHIV2QC3- Anti HIV2: Quality Control Serum: Sample 3 |
14/B654-03 | QCRRUBQC1-Anti-Rubella Quality Control Serum: Sample 1 |
14/B655-03 | QCRVZVQC1-Anti VZV: Quality Control Serum: Sample 1 |
15/100 | Influenza Antigen B/Utah/9/2014 (Cell Derived) |
15/104 | Influenza Antigen A/South Australia/55/2014 Cell derived |
15/106 | Ancrod |
15/130-001 | Clinical Virology Multiplex I: Immunodeficiency panel working reagent for Nucleic Acid Amplification Tests (NAT) |
15/134 | Influenza Anti-A Switzerland/9715293/2013-Like HA serum |
15/136 | EBOV RNA NP-VP35-GP in-run control |
15/138 | EBOV RNA VP40-L in-run control |
15/140 | Batroxobin |
15/146 | Influenza Virus Infectious B/Brisbane/60/2008 |
15/148 | Influenza Virus Infectious NIB-92 |
15/150 | Influenza anti-B/Phuket/3073/2013 HA serum |
15/154 | Influenza Virus Infectious NIB-93 |
15/158 | Influenza Virus Infectious NYMC X-263 |
15/160 | Influenza Virus Infectious NIBRG-306 |
15/174 | Anti-dsDNA serum |
15/180 | Blood Coagulation Factor XI, Plasma Human 2nd IS |
15/182 | 7th British Working Standard for Blood Coagulation Factors II, IX, X Concentrate |
15/184 | Influenza Virus Infectious NYMC X-263B |
15/188 | Influenza Virus Infectious NYMC X-263A |
15/192 | Influenza Virus Infectious A/Hong Kong/4801/2014 |
15/194 | Influenza Virus Infectious NYMC X-257A |
15/196 | Influenza Virus Infectious NYMC X-261 |
15/212 | Influenza Virus Infectious NYMC BX-53C |
15/220 | Anti-EBOV plasma, human (WHO Reference Reagent) |
15/222 | EBOV RNA NP-VP35-GP (WHO Reference Reagent) |
15/224 | EBOV RNA VP40-L (WHO Reference Reagent) |
15/234 | Influenza Virus Infectious B/Texas/2/2013 41340 E7 |
15/238 | Influenza Antigen A/New Caledonia/71/2014 (NYMCX-257A)(Egg derived antigen) |
15/240 | Erythropoietin Antibody Reference Panel A (1st WHO Reference Panel) |
15/242 | Erythropoietin Antibody Reference Panel B (1st WHO Reference Panel) |
15/248 | Influenza Anti A/Anhui/1/2013 (H7) HA Serum (Sheep SH644 & SH645) |
15/250 | Influenza Virus Infectious NYMC BX-31 |
15/252 | Influenza Virus Infectious A/California/7/2009 |
15/262 | Anti- EBOV Convalescent Plasma Pool - Sierra Leone (International Reference Reagent) |
15/274 | Influenza Virus Infectious NYMC BX-59A |
15/294 | Influenza virus infectious NYMC BX-59B |
15/298 | Influenza Virus Infectious B/Brisbane/46/2015 |
15/300 | Influenza Virus Infectious NYMC BX-35 41950 E11 |
15/312 | Influenza Anti-B/Brisbane/60/2008 HA Serum |
15/B658-03 | QCRLYMEQC1 - Anti-Lyme QC1 |
15/B661-03 | QCRLYMEIgMQC1 - IgM Anti-Lyme QC1 |
15/B664-02 | QCRMUMPSQC1 - Anti-Mumps Quality Control Reagent Sample 1 |
15/B667-02 | QCRMEASQC1 Anti-MeaslesQC1 |
15/B669-02 | QCRHCVQC1-Anti-HCV Quality Control Serum: Sample1 |
15/B671-02 | QCRHIV1P24QC1-HIV1 p24 Antigen: Quality Control Serum: Sample1 |
15/B673-02 | QCRSYPHQC1-Anti-Syphilis Quality Control Serum: Sample 1 |
15/B675-03 | QCRSYPHQC2-Anti-Syphilis Quality Control Serum: sample2 |
15/B678-02 | QCRPARVB19QC1 Anti-Parvovirus B19QC1 |
15/B680-01 | QCRHBsQC1- Anti HBs Quality Control Serum: Sample 1 |
16/104-001 | Norovirus GII Working reagent for Nucleic Acid Amplification Techniques |
16/106 | Influenza antigen A/California/7/09 (H1N1) (NYMC-X181) |
16/110-001 | Zika Virus Working Reagent for Nucleic Acid Amplification Testing (NAT) |
16/114 | Influenza anti - A/California/7/09 HA serum |
16/118 | Influenza Antigen B/Brisbane/60/2008 (NYMC BX-35) (Egg Derived) |
16/120 | WHO 1st International Reference Panel for Genomic JAK2 V617F |
16/124-001 | Zika Virus run Control (NAT) |
16/158 | Influenza Antigen B/Phuket/3073/2013 |
16/166 | Diphtheria Antitoxin Equine DI. |
16/182 | Influenza Anti-A/Hong Kong/4801/2014-like HA Serum |
16/192 | Influenza Anti-B/Brisbane/60/2008 HA serum |
16/194 | HIV-1 RNA Proposed-4th International Standard |
16/200 | Influenza Virus Infectious NIB-58 |
16/208 | Influenza Virus Infectious NIB-97 42090 E7 |
16/238 | Influenza Antigen A/Anhui/1/2013 (NIBRG-268) (H7N9) |
16/242 | Influenza Virus Infectious NIB-98 42110 E7 |
16/248 | Influenza Virus Infectious NYMC X-275 42020 E11 |
16/268 | Influenza Virus Infectious X-273 |
16/270 | Influenza Virus Infectious IVR-180 42400 E3/D7/E1 |
16/274 | Influenza Virus Infectious X-275A 42010 E13 |
16/282 | Influenza Virus Infectious X-285 42430 ExE1 |
16/286 | Influenza Antigen A/Hong Kong/4801/2014 (NYMC X-263B) |
16/288 | Influenza Virus Infectious X-283A 42420 ExE1 |
16/290 | Influenza Virus Infectious X-285A 42440 ExE1 |
16/292 | Influenza Antigen A/Singapore/GP1908/2015 (IVR-180) |
16/298 | Influenza Antigen A/Michigan/45/2015 (NYMC X-275) |
16/304 | Influenza anti-A/Michigan/45/2015-like HA serum |
16/344 | WHO Anti-EBOV Convalescent Plasma (International Reference Panel) |
16/354 | Influenza Virus Infectious A/Michigan/45/2015 41710 E4 |
16/360 | Influenza Virus Infectious NIB-96 41920 E7 |
16/362 | Influenza Virus Infectious NYMC X-291 42530 E8 |
16/366 | Influenza Virus Infectious NYMC X-291A 42540 E8 |
16/B683-04 | QCRPARVB19IgMQC1 - IgM Anti-Parvovirus B19 Quality Control Reagent 1 |
16/B685-02 | QCRHIV2QC2-Anti HIV2:Quality Control Serum: Sample2 |
16/B687-01 | QCRHIV1RTDQC1- Anti-HIV1 Quality Control Serum: Sample 1 for Rapid Test Devices |
16/B693-01 | QCRCMVIgMQC1 IgM Anti-CMV QC1 |
16/B695-01 | QCRTOXOIgMQC1 IgM Anti-Toxoplasma gondii QC1 |
16/B704-01 | QCRTHBcQC1-Total Anti-HBc Quality Control Serum: Sample 1 |
16/B706-01 | QCRHIV1p24QC2-HIV1 p24 Antigen: Quality Control Serum: Sample2 |
17/106 | Influenza Anti-A/Michigan/45/2015-like HA Serum |
17/126 | Influenza Virus Infectious NYMC BX-63A 42780 E10/E1 |
17/154 | Influenza Antigen A/Michigan/45/2015 (NYMC X-275) |
17/156 | Influenza Virus Infectious CNIC-1701 42910 E9 |
17/162 | Influenza Virus Infectious NYMC X-299 42920 E10 |
17/164 | Influenza Virus Infectious B/Maryland/15/2016 42800 E5 |
17/184 | Influenza Virus Infectious NIB-103 42610 E7 |
17/194 | Influenza Virus Infectious NIB-104 |
17/196 | Influenza Virus Infectious A/Singapore/INFIMH-16-0019/2016 |
17/B710-01 | QCRTOXOQC1 - Anti-Toxoplasma gondii Quality Control Reagent Sample 1 |
17/B718-01 | QCRHBsGQC2-HBsAg Quality Control Serum: Sample2 |
234 | IPV ELISA MAbs Type 1, 2 and 3 (Type 1; No: 234) |
2BADS | Anti-Brucella Abortus Serum, Bovine (International Standard) |
2CPBETAAT | Clostridium Perfringens Beta Antitoxin (2nd International Standard) |
2CPEPAT | Clostridium Perfringens Epsilon Antitoxin (2nd International Standard) |
520 | IPV ELISA MAbs Type 1, 2 and 3 (Type 3; No: 520) |
59/015 | Gas Gangrene (Cl. Perfringens(Cl. Welchii) Type A), Equine |
59/016 | Corticotrophin (ACTH), Porcine (3rd International Standard) |
59/021 | Botulinum Antitoxin Equine Type A |
60/001 | Botulinum Antitoxin Equine Type B |
60/013 | Tetanus Antitoxin, Equine, for Bioassay |
61/001 | Botulinum Antitoxin Equine Type D (1st International Standard) |
62/001 | Serum Gonadotrophin, Equine (2nd International Standard) |
62/014 | Lysine Vasopressin, Porcine |
63/005 | Gas Gangrene Antitoxin (Cl. Histolyticum), Equine |
63/007 | Diphtheria Antitoxin, Equine, for Flocculation Test |
64/002 | Rheumatoid Arthritis Serum |
64/014 | Gas Gangrene Antitoxin (Cl. Septicum), Equine |
64/024 | Gas Gangrene Antitoxin (Cl. Oedematiens), Equine |
65/093 | Anti-Thyroglobulin Serum, Human (International Reference reagent) |
65/119 | Renin, Porcine |
65/122 | Long-acting Thyroid Stimulator, Human |
66/021 | Tetanus Antitoxin, Equine, for Flocculation Test |
66/138 | Gastrin II, Porcine |
66/153 | Diphtheria Antitoxin, Equine |
66/233 | Anti-Nuclear Factor Serum (Homogenous) Human |
66/387 | Anti-thyroid Microsome Serum, Human |
67/037 | Immunoglobulin D (IgD) Serum, Human |
67/086 | Immunoglobulins G, A, M Serum Human (International Standard) |
67/099 | Immunoglobulins G, A & M Serum Human |
67/182 | Anti-Rubella Serum, Human |
67/183 | Primary Biliary Cirrhosis Serum, Human |
68/340 | Anti-Nucleolar Factor Plasma, Human |
68/356 | Renin, Human (International Standard) |
69/017 | Diphtheria Toxoid, Plain |
69/065 | Autoimmune Antibody to Human Spermatazoa |
69/194 | Glucagon, Porcine (First International Standard) |
70/302 | Angiotensin II (25µg) |
71/281 | Anti-Malaria Plasma P Vivax |
71/326 | Anti-Malaria Plasma Vivax Ng2 |
71/328 | Angiotensin I |
72/092 | Anti-malaria Plasma: Plasmodium falciparum (Ghana) |
72/096 | Anti-Malaria Serum (P.Malariae) |
72/341 | Anti-Malaria Plasma P Falciparum |
72/345 | Anti-Malaria Plasma P Falciparum |
72/348 | Anti-Malaria Plasma P Vivax |
73/515 | Anti-D (Rho) Antibodies, Human |
73/545 | Placental Lactogen, Human (International Reference Preparation) |
73/554 | Cholera Vaccine (Inaba) |
73/556 | Cholera Vaccine (Ogawa) |
73/601 | Carcinoembryonic Antigen (CEA), Human (1st International Reference Preparation) |
74/520 | Serum Proteins (Other than Immunoglobulins) Human |
74/555 | Corticotrophin (ACTH), Human |
74/586 | Corticotrophin (ACTH), Porcine (International Working Standard) |
75/506 | Cocksfoot Pollen Extract |
75/533 | Chorionic Gonadotrophin, Human, for Radioiodination |
75/535 | Chorionic Gonadotrophin beta, Human, for Radioiodination |
75/551 | Chorionic Gonadotrophin beta Subunit, Human (International Reference Preparation) |
75/569 | Chorionic Gonadotrophin alpha subunit, Human (International Reference Preparation) |
75/595 | Blood Coagulation Factor Xa, Bovine |
76/508 | Chorionic Gonadotrophin alpha Subunit, Human, for Radioiodination |
76/515 | Mannan (C. Albians) Purified |
76/522 | Opacity 5IRP WHO International Standard |
76/525 | Anti-Birch Pollen Serum, Human |
76/547 | Influenza anti A/Victoria/3/75 Serum(goat) |
76/575 | Oxytocin(4th International Standard) |
77/503 | Anti-Cocksfoot Serum, Human |
77/512 | Lysine Vasopressin(1st International Standard) |
77/531 | Influenza anti A/New Jersey/8/76(H1N1) Serum |
77/568 | Influenza anti B/Hong Kong/8/73 Serum |
77/584 | Anti-D Pteronyssinus Serum, Human |
77/600 | Mannan (C. Albicans) Purified |
77/616 | Twelve Grass Pollen Extract |
77/643 | Secretin |
77/662 | Acarus Siro Extract |
77/664 | Glycyphagus destructor Extract |
78/517 | Tyrophagus Putrescentiae Extract |
78/543 | Kininogenase (Porcine, Pancreatic) (Formerly 1st International Standard) |
78/545 | Anti-Aspergillus fumigatus Serum, Human |
78/554 | Luteinizing Hormone, Pituitary, alpha subunit (International Standard) |
78/556 | Luteinizing Hormone, Pituitary, beta subunit (International standard) |
78/560 | Influenza Antigen A/Texas/1/77 |
78/569 | Influenza anti A/Texas/1/77 Serum |
78/575 | Aspergillus Fumigatus Extract |
78/582 | Tyrophagus Longior Extract |
78/628 | Bee Venom |
79/500 | Parathyroid Hormone, Human (1st International Ref. Preparation) |
79/516 | Influenza anti A/Brazil/11/78 Serum (goat) |
79/552 | Influenza Antigen A/USSR/92/77 |
79/558 | Influenza Antigen A/USSR/92/77 |
79/560 | Influenza Antigen A/Brazil/11/78 |
79/568 | Influenza Antigen B/Hong Kong/8/73 |
79/572 | Prekallikrein Activator (PKA), Human |
80/505 | Growth Hormone, Human, Pituitary. WHO International Standard |
80/517 | Influenza Antigen A/Bangkok/1/79 |
80/519 | Influenza Antigen B/Singapore/222/79 |
80/523 | Influenza anti B/Singapore/222/79 Serum |
80/525 | Influenza anti A/Bangkok/1/79 Serum |
80/590 | Tetracosactide. International Ref. Preparation |
81/535 | Luteinizing Hormone, Human, Pituitary (3rd International Standard) |
81/565 | Thyroid Stimulating Hormone, Human. WHO International Standard |
82/508 | Parathyroid Hormone, Human-Type, Synthetic (1-34) fragment |
82/512 | Parathyroid Hormone, Bovine-Type, Synthetic (1-34) fragment |
82/518 | Dermatophagoides Pteronyssinus Extract. WHO International Standard |
82/520 | Timothy Pollen Extract. WHO International Standard |
82/585 | Anti Poliovirus serum types 1,2 and 3 (3rd International Standard) |
82/587 | Interferon Gamma (Human, Leukocyte derived) |
82/632 | Parathyroid Hormone, Bovine. WHO International Standard |
82/652 | Human Serum Vitamin B12, Pernicous anaemia |
83/500 | Insulin, Human. WHO International Standard |
83/501 | Beta Thromboglobulin, Purified Human. WHO International Standard |
83/505 | Plaet Factor 4 Human, Purified. WHO International Standard |
83/511 | Insulin, Bovine. WHO International Standard |
83/514 | Interferon alpha-1D, (Human rDNA derived) WHO International Standard |
83/515 | Insulin, Porcine. WHO International Standard |
83/537 | Influenza Antigen A/Philippines/2/82 |
83/545 | Influenza anti A/Philippine/2/82 Serum |
83/550 | Influenza Antigen A/Brazil/11/78 |
83/573 | Prolactin, Human (4th WHO International Standard.) |
83/575 | Follicle Stimulating Hormone, Pituitary. WHO International Standard |
84/514 | Proinsulin, Bovine. International Ref. Preparation |
84/522 | Birch Pollen Extract. WHO International Standard |
84/528 | Proinsulin, Porcine. International Ref. Reagent |
84/538 | Influenza Antigen A/Chile/1/83 |
84/542 | Influenza Antigen B/Norway/1/84 |
84/581 | Short Ragweed Pollen Extract. WHO International Standard |
84/614 | Calcitonin, ASU 1-7 Eel Calcitonin Analogue (Elcatonin) WHO International Standard |
84/628 | Anti-c Serum, Human |
84/636 | Influenza anti B/USSR/100/83 Serum |
84/640 | Influenza anti A/Chile/1/8 Serum |
84/677 | Influenza anti A/equine/Miami/63 (H3N8) Serum(goat) |
84/685 | Dog (Canis Familiaris) Hair Dander Extract. WHO International Standard |
85/506 | C-Reactive Protein, Human. WHO International Standard |
85/516 | Influenza anti A/Equine/Kentucky/1/81 HA Serum |
85/520 | Influenza Antigen A/Equine/Kentucky/1/81 |
85/522 | Thyroid Stimulating Hormone beta subunit |
85/551 | Anti-Rye Grass Serum, Human |
85/616 | Haemoglobin F Lysate, Raised. WHO Reference Reagent |
85/669 | Atrial Natriuretic Factor, Human. WHO International Standard |
86/500 | Interleukin- 2 (Human, rDNA derived)(2nd International Standard) |
86/536 | Angiotensin I Human Type Synthetic |
86/538 | Angiotensin II (2.5µg) |
86/552 | Interleukin-1 Beta (Human, rDNA derived) |
86/576 | Influenza Antigen A/Mississippi/1/85 |
86/590 | Influenza anti A/Mississippi/1/85 Serum |
86/592 | Influenza anti B/Ann Arbor/1/86/HA Serum |
86/630 | Influenza Antigen B/Ann Arbor/1/86 |
86/632 | Interleukin-1 alpha (Human rDNA derived) WHO International Standard |
86/678 | Interleukin-1 alpha (Human, rDNA derived) |
86/680 | Interleukin-1 beta (Human, rDNA derived) WHO International Standard |
86/690 | Inhibin, Porcine WHO International Standard |
87/510 | Influenza Antigen A/Equine/Miami/63 |
87/578 | Influenza anti A/Leningrad/360/86 Serum |
87/584 | Influenza Antigen A/Leningrad/360/86 |
87/586 | Interferon Gamma (Human, rDNA derived) |
87/640 | Tumour Necrosis Factor beta (Human, rDNA derived) WHO Reference Reagent |
87/654 | Anti-Ferritin Monoclonal Antibody (1) |
87/662 | Anti-Ferritin Monoclonal Antibody (2) |
87/714 | Influenza Antigen A/Sichuan/2/87 |
87/774 | Influenza Antigen B/Victoria/2/87 |
88/522 | Bordela pertussis (Whole cell vaccine) 3BRP |
88/532 | Tumour Necrosis Factor alpha (Mouse, rDNA derived) |
88/554 | Influenza Antigen B/Beijing/1/87 |
88/556 | Calcitonin, Eel WHO International Standard |
88/638 | Thyroxine-binding globulin. WHO International Standard |
88/646 | Granulocyte Macrophage Colony Stimulating Factor (Human, rDNA derived) WHO International Standard |
88/654 | Influenza Antigen A/England/427/88 |
88/656 | Interleukin-4 (Human, rDNA derived) WHO International Standard |
88/672 | Influenza anti A/Sichuan/2/87 Serum |
88/678 | Influenza anti B/Beijing/1/87 Serum |
88/846 | Influenza anti A/England/427/88 Serum |
89/512 | Macrophage Colony Stimulating Factor (CSF-1) (Human rDNA derived) WHO International Standard |
89/514 | Transforming Growth Factor beta-1 (Human, rDNA derived) |
89/516 | Transforming Growth Factor beta-1 (Bovine) |
89/518 | Transforming Growth Factor beta-2 (Bovine) |
89/520 | Interleukin-8 (Human, rDNA derived) WHO International Standard |
89/530 | Anti-Bordela pertussis serum (Human) |
89/544 | Renin, Human, rec DNA |
89/548 | Interleukin-6 (Human, rDNA derived) WHO International Standard |
89/568 | Influenza Antigen A/OMS/5389/88 |
89/594 | Bordela pertussis (W28) LPS 2ug |
89/596 | Bordela pertussis anti-agglutinogen 1(rabbit) |
89/598 | Bordela pertussis anti-agglutinogen 2 (rabbit) |
89/600 | Bordela pertussis anti-agglutinogen 3 (rabbit) |
89/620 | Calcitonin, Human. WHO International Standard |
89/666 | Haemoglobin A2 Lysate, Raised. WHO Reference Reagent |
89/670 | Bordela pertussis (W28) LPS25ug |
90/500 | Influenza Antigen A/Shanghai/16/89 |
90/502 | Influenza Antigen A/Guizhou/54/89 |
90/504 | Influenza anti A/Guangdong/39/89 Serum |
90/520 | Bordela pertussis, filamentous haemagglutinin (FHA) |
90/530 | Interleukin-7 (Human, rDNA derived) WHO Reference Reagent |
90/534 | Mumps Vaccine (Live) WHO Reference Reagent |
90/586 | Interleukin-5 (Human, rDNA derived) WHO Reference Reagent |
90/636 | HIV-1 P24 Antigen WHO International Standard |
90/654 | Bordela pertussis 69kD |
90/690 | Anti-Varicella-Zoster Antibody |
90/696 | Transforming Growth Factor beta-2, Human, rec DNA |
90/712 | Basic Fibroblast Growth Factor (Human, rDNA derived) WHO International Standard |
90/784 | Influenza Virus infectious NIB-26 (H3N2) |
91/510 | Interleukin-3 (Human, rDNA derived) WHO International Standard |
91/530 | Epidermal Growth Factor (Human, rDNA derived) WHO International Standard |
91/550 | Epidermal Growth Factor (1-52) (Human, rDNA derived) WHO Reference Reagent |
91/554 | Insulin-like growth Factor 1 WHO International Standard |
91/562 | Anti-D for use with papain preparation 92/658 |
91/612 | Influenza anti A/Taiwan/1/86 Serum |
91/624 | Inhibin A, Human, recombinant WHO International Standard |
91/626 | Activin A, Human, Recombinant. WHO Reference Reagent |
91/656 | Interleukin-4 (Mouse, rDNA derived) |
91/658 | Granulocyte Macrophage Colony Stimulating Factor (Mouse rDNA derived) |
91/662 | Interleukin-3 (Mouse, rDNA derived) |
91/670 | Influenza Virus infectious NIB-27 (H1N1) |
91/678 | Interleukin-9 (Human,rDNA derived) WHO Reference Reagent |
91/682 | Stem Cell Factor (Human rDNA derived) WHO Reference Reagent |
91/688 | Rubella Vaccine (Live) 1st International Reference Reagent |
92/510 | Follicle Stimulating Hormone, Human, recombinant. WHO International Standard |
92/512 | Follicle Stimulating Hormone, urofollitropin Human Urinary WHO International Standard |
92/518 | Macrophage Inflammatory Protein-1 alpha (Human, rDNA derived) |
92/520 | Rantes (Human, rDNA derived) |
92/530 | Influenza Antigen A/Texas/36/91 |
92/582 | Influenza anti B/Yamagata/16/88 Serum |
92/628 | Influenza Antigen B/Yamagata/16/88 |
92/632 | Influenza anti A/Beijing/352/89 (H3N2) Serum |
92/644 | Interleukin-1 Receptor Antagonist (IL-1ra) (Human, rDNA derived) |
92/648 | Measles Vaccine (Live) 2nd International Reference Reagent |
92/654 | Plasminogen Activator Inhibitor-1 (PAI-1), plasma Human WHO International Standard |
92/658 | Papain preparation for use with Anti-D preparation 91/562 |
92/680 | Serum amyloid A protein. WHO International Standard |
92/734 | Influenza Virus infectious A/Beijing/32/92 (H3N2) |
92/738 | Influenza Virus infectious A/Shanghai/24/90 |
92/788 | Interleukin-11 (Human, rDNA derived) WHO Reference Reagent |
92/794 | Monocyte Chemoattractant Protein-1 (Human,rDNA derived) |
93/500 | Influenza Antigen A/Beijing/32/92 |
93/516 | Influenza Antigen A/Shanghai/24/90 |
93/518 | Influenza anti A/Beijing/32/92 (H3N2) Serum |
93/522 | Influenza anti A/Shanghai/24/90 (H3N2) Serum |
93/556 | Nerve Growth Factor (Human, rDNA derived) WHO Reference Reagent |
93/560 | Insulin-like growth Factor Binding Protein-3 |
93/562 | Leukaemia Inhibitory Factor (Human, rDNA derived) WHO Reference Reagent |
93/564 | Oncostatin M (Human, rDNA derived) WHO Reference Reagent |
93/566 | Interleukin-2 (Mouse, rDNA derived) |
93/568 | Influenza Virus infectious A/Beijing/359/89 (H3N2) |
93/572 | Influenza Virus infectious A/Guizhou/54/89 (H3N2) |
93/574 | Bone morphogenetic Protein-2 (Human, rDNA derived) WHO Reference Reagent |
93/668 | Interleukin-1 beta (Mouse, rDNA derived) |
93/672 | Interleukin-1 alpha (Mouse, rDNA derived) |
93/686 | Influenza Virus infectious A/Shangdong/9/93 (H3N2) |
93/692 | Influenza Virus infectious B/Panama/45/90 |
93/722 | Interleukin-10 (Human rDNA derived) WHO Reference Reagent |
93/730 | Interleukin-6 (Mouse, rDNA derived) |
93/740 | Interleukin-7 (Mouse, rDNA derived) |
93/816 | Influenza Virus infectious A/Harbin/15/92 (H3N2) |
94/500 | Influenza Antigen B/Panama/45/90 |
94/504 | Influenza anti A/Shanghai/9/93 Serum |
94/516 | Influenza Antigen A/Shangdong/9/93 |
94/520 | Influenza anti B/Panama/45/90 Serum |
94/532 | Pertussis Vaccine (Whole Cell) WHO International Standard |
94/572 | Ferritin, Human, recombinant. WHO International Standard |
94/622 | Interleukin-13 (Human, rDNA derived) WHO Reference Reagent |
94/674 | Thyroid Stimulating Hormone, Human recombinant WHO Reference Reagent |
94/684 | Ciliary Neurotrophic Factor (Human, rDNA derived) WHO Reference Reagent |
94/718 | Staphylokinase, rec (STAR) |
94/728 | Plaet-derived Growth Factor-BB (Human, rDNA derived) WHO International Standard |
94/730 | Tissue Plasminogen Activator (tPA) Antigen in Plasma WHO International Standard |
94/754 | Interferon Omega (Human, rDNA derived) WHO International Standard |
94/762 | Influenza Virus infectious RESVIR-8 (H3N2) |
94/766 | Influenza Virus infectious NIB-34 (H3N2) |
94/784 | Interferon alpha (Human, leukocyte derived)WHO International Standard |
94/786 | Interferon alpha Concensus Sequence (Human rDNA derived) WHO International Standard |
94/790 | MAPREC analysis of Poliovirus type 3 (Sabin). Synthetic DNA * 472-C WHO International Standard |
95/510 | Influenza Antigen A/Texas/36/91 |
95/516 | Influenza Antigen A/Johannesburg/33/94 |
95/522 | Anti-HBc (Anti-hepatitis B core antigen) WHO International Standard |
95/524 | Influenza anti A/Johannesburg/33/94 Serum |
95/528 | Folate, Whole Blood Haemolysate WHO International Standard |
95/542 | MAPREC analysis of Poliovirus type 3 (Sabin) Synthetic DNA 0.9% 472-C WHO International Standard |
95/544 | Interleukin-12 (Human, rDNA derived) WHO Reference Reagent |
95/554 | Interleukin-15 (Human, rDNA derived) WHO Reference Reagent |
95/564 | Single Chain Urinary-Type Plasminogen Activator (SCuPA), (Non-Glyc) |
95/566 | Interferon alpha-2b (Human, rDNA derived) WHO International Standard |
95/568 | Interferon Alpha n1 (Human lymphoblastoid cell derived) WHO International Standard |
95/572 | Interferon alpha-1/8 (Human, rDNA derived) WHO International Standard |
95/574 | Interferon Alpha n3 (Human, leukocyte derived) WHO International Standard |
95/580 | Interferon alpha-2c (Human, rDNA derived) WHO International Standard |
95/584 | Anti-hepatitis E Serum, Human WHO Reference Reagent |
95/646 | Parathyroid Hormone 1-84, human, recombinant (1st International Standard) |
95/650 | Interferon alpha-2a (Human, rDNA derived) WHO International Standard |
95/668 | Single Chain Urinary-Type Plasminogen Activator (SCuPA), (Glyc) |
95/674 | Anti-Meningococcal Serogroup A mAb |
95/678 | Anti-Meningococcal Serogroup C mAb |
96/528 | Soluble Tumour Necrosis Factor Receptor Type 1, (Human, rDNA derived) |
96/532 | FMS-like tyrosine kinase 3 ligand (Human, rDNA derived) WHO Reference Reagent |
96/534 | Brain-derived Neurotrophic Factor (Human, rDNA derived) WHO Reference Reagent |
96/538 | Insulin-like growth Factor-II (Human rDNA derived) WHO Reference Reagent |
96/556 | Hepatocyte Growth Factor/Scatter Factor (precursor), (Human rDNA derived) WHO International Standard |
96/564 | Hepatocyte Growth Factor/Scatter Factor (Human, rDNA derived) WHO Reference Reagent |
96/572 | MAPREC analysis of Poliovirus type 3 (Sabin) Low virus reference 0.7%472-C WHO Reference Reagent |
96/578 | MAPREC analysis of Poliovirus type 3 (Sabin) High virus reference 1.1%472-C WHO Reference Reagent |
96/602 | Luteinizing Hormone, Human, recombinant WHO International Standard |
96/666 | Anti-Human Globulin International Reference Reagent |
96/668 | Prostate Specific Antigen (free) WHO International Standard |
96/784 | Inhibin B, Human WHO Reference Reagent |
96/830 | Influenza Virus infectious A/Bayern/7/95 |
96/836 | Influenza Virus infectious RESVIR-9 (H3N2) |
96/848 | Influenza Virus infectious A/Shenzhen/227/95 (H1N1) |
96/850 | Influenza Virus infectious NIB-39 (H1N1) |
97/518 | Influenza Antigen A/Johannesburg/82/96 |
97/538 | Anti-Granulocyte Macrophage Colony Stimulating Factor Serum |
97/550 | Islet Cell Antibodies WHO Reference Reagent |
97/558 | Bordela pertussis anti 69kD serum (sheep) |
97/562 | Blood Coagulation Factors IXa Concentrate, Human, recombinant(1st I.S.) |
97/564 | Bordela pertussis anti FHA serum (sheep) |
97/572 | Bordela pertussis PT anti serum (sheep) |
97/574 | Bordela pertussis anti Fim3 serum (sheep) |
97/584 | Influenza Antigen A/Equine/Newmarket/2/93 |
97/594 | Leptin, Human, Recombinant WHO International Standard |
97/596 | Influenza Antigen A/Equine/Newmarket/1/93 |
97/600 | Interleukin-2 Soluble Receptor (human, rDNA derived) |
97/610 | Influenza anti A/equine/Newmarket/1/93 Serum |
97/612 | Influenza anti- A/Nanchang/933/95 (H3N2) HA serum |
97/614 | Influenza anti A/Equine/Newmarket/2/93 (H3N8) HA Serum (SH-376) |
97/626 | Leptin, Mouse, Recombinant WHO International Standard |
97/642 | Bordela pertussis anti serum (mouse) 1RR |
97/646 | Anti-Hepatitis A Immunoglobulin, Human (W1041) WHO International Standard |
97/648 | Anti-Measles serum (3rd International Standard) |
97/692 | Influenza Virus infectious IVR-108 (H3N2) |
97/714 | Prolactin, Human, recombinant. WHO Reference Reagent |
97/722 | Influenza Virus infectious A/duck/Sing-Q/119/97 (H5N3) |
97/726 | Influenza Virus infectious B/Harbin/7/94 |
97/748 | Influenza Antigen B/Harbin/7/94 |
97/756 | MAPREC analysis of Poliovirus type 2 (Sabin), low virus reference 0.65%481-G. WHO Reference Reagent |
97/758 | MAPREC analysis of Poliovirus type 2 (Sabin) Synthetic DNA 0.67%481-G WHO International Standard |
97/760 | Influenza Antigen A/Beijing/262/95 |
98/524 | MAPREC analysis of Poliovirus type 2 (Sabin) Synthetic DNA, *481-G WHO International Standard |
98/544 | Influenza Virus infectious RESVIR-13 (H3N2) |
98/572 | Diphtheria and Tetanus Antitoxin, Guinea Pig Serum |
98/574 | Somatropin WHO International Standard |
98/580 | Prolactin Human, recombinant, glycosylated WHO Reference Reagent |
98/582 | Prolactin, Human, recombinant, non-glycosylated WHO Reference Reagent |
98/586 | Calcitonin, Salmon. WHO International Standard |
98/596 | MAPREC analysis of Poliovirus type 2 (Sabin), high virus reference 1.21% 481-G. WHO Reference Reagent |
98/600 | Influenza Virus infectious NIB-40 (H5N3) |
98/604 | Influenza anti B/Harbin/7/94/HA Serum |
98/610 | Influenza Virus infectious ARIV-1 (H5N3) |
98/666 | Influenza anti A/Hong Kong/489/97 (H5N1) Serum (sheep) |
98/686 | Negative Control Guinea Pig Serum (Diphtheria and Tetanus Serology) |
98/708 | Haemiglobincyanide WHO International Standard |
98/714 | Tissue Plasminogen Activator, Human, Recombinant WHO International Standard |
98/718 | Neurotrophin 3 |
98/722 | Meningococcal group A polysaccharide |
98/762 | Influenza Virus infectious Resvir-14 (H3N2) |
98/772 | Influenza anti A/Beijing/262/95 Serum |
98/774 | Influenza Antigen B/Shangdong/7/97 |
98/778 | Influenza Virus infectious A/Sichuan/346/98 (H3N2) |
99/506 | Anti-PT S1 subunit Monoclonal Antibody (1B7) |
99/508 | Anti-PT S1 subunit Monoclonal Antibody (1D7) |
99/510 | Anti-PT S1 subunit Monoclonal Antibody (3F11) |
99/512 | Anti-PT S1 subunit Monoclonal Antibody (10D6) |
99/514 | Anti-PT S1 subunit Monoclonal Antibody (8G4) |
99/516 | Anti-PT S1 subunit Monoclonal Antibody (E1E) |
99/518 | Anti-PT S1 subunit Monoclonal Antibody (E2E) |
99/520 | Anti-PT S1 subunit Monoclonal Antibody (3F10) |
99/522 | Anti-PT S1 subunit Monoclonal Antibody (11D9) |
99/524 | Anti-PT S1 subunit Monoclonal Antibody (4D10) |
99/526 | Anti-PT S23 subunit Monoclonal Antibody (11E6) |
99/528 | Anti-PT S23 subunit Monoclonal Antibody (10C9) |
99/530 | Anti-PT S23 subunit Monoclonal Antibody (10B5) |
99/532 | Anti-PT S23 subunit Monoclonal Antibody (G9A) |
99/534 | Anti-PT S23 subunit Monoclonal Antibody (3F6) |
99/536 | Anti-PT S2 subunit Monoclonal Antibody (3A12) |
99/538 | Anti-PT S2 subunit Monoclonal Antibody (2H3) |
99/540 | Anti-PT S2 subunit Monoclonal Antibody (9G8) |
99/542 | Anti-PT S3 subunit Monoclonal Antibody (7E10) |
99/544 | Anti-PT S3 subunit Monoclonal Antibody (7G11) |
99/546 | Anti-PT S3 subunit Monoclonal Antibody (4G5) |
99/548 | Anti-PT S3 subunit Monoclonal Antibody (2E12) |
99/550 | Anti-PT S3 subunit Monoclonal Antibody (6F8) |
99/552 | Anti-PT S3 subunit Monoclonal Antibody (10B8) |
99/554 | Anti-PT S4 subunit Monoclonal Antibody (7F2) |
99/556 | Anti-PT S4 subunit Monoclonal Antibody (6B3) |
99/558 | Anti-PT S4 subunit Monoclonal Antibody (6G8) |
99/560 | Anti-PT S4 subunit Monoclonal Antibody (9F3) |
99/562 | Anti-PT S4 subunit Monoclonal Antibody (1H2) |
99/564 | Anti-PT S4 subunit Monoclonal Antibody (9C6) |
99/566 | Anti-PT S4 subunit Monoclonal Antibody (6D6) |
99/568 | Anti-PT S5 subunit Monoclonal Antibody (7E3) |
99/570 | Anti Filamentous Haemagglutinin Monoclonal Antibody (1C6) |
99/572 | Anti-Filamentous Haemagglutinin Monoclonal Antibody (2E9) |
99/574 | Anti Filamentous Haemagglutinin Monoclonal Antibody (12G10) |
99/586 | Influenza Antigen B/Yamanashi/166/98 |
99/614 | Influenza Antigen A/Sydney/5/97 |
99/616 | Yellow Fever Vaccine. WHO International Standard |
99/624 | Influenza Antigen A/Sydney/5/97 |
99/634-007 | HIV-1 RNA Working Reagent 1 (PWS-1) for NAT Assays |
99/636-007 | HIV-1 RNA Working Reagent 2 for NAT assays |
99/642 | Chorionic Gonadotrophin, nicked, human. WHO Reference Reagent |
99/650 | Chorionic Gonadotrophin, beta subunit, human. WHO Reference Reagent |
99/666 | Anti-HPA-5b (Minimum Potency) WHO Reference Reagent |
99/674-017 | HIV-2 (antibody) Monitor Sample |
99/688 | Chorionic Gonadatrophin, intact, Human. WHO Reference Reagent |
99/692 | Chorionic Gonadotrophin, nicked beta subunit, Human WHO Reference Reagent |
99/706 | Anti-Meningococcal human reference serum CDC1992 |
99/708 | Chorionic Gonadatrophin, beta core fragment, Human WHO Reference Reagent |
99/710-021 | HIV-1 (antibody) (1 in 5 dilution) British Working Standard |
99/714 | Influenza Antigen A/Singapore/1/57 (H2N2) |
99/720 | Chorionic Gonadotrophin, alpha subunit, Human (purified) |
99/728 | Anti-D Immunoglobulin Control |
99/750-022 | HIV-1 (antibody) British Working Standard) |
99/824 | Influenza Virus infectious RESVIR 16 (H3N2) |
99/828 | Influenza Antigen B/Yamanashi/166/98 |
99/836 | Anti-D Minimum Potency Standard for blood grouping reagents WHO International Standard |
AFP | Alpha-Foetoprotein. WHO International Standard |
B2M | Beta-2 Microglobulin. WHO International Standard |
BUSB | Botulinum Antitoxin Equine Type B. WHO International Standard |
CDS | Anti-Canine Distemper Serum. WHO International Standard |
CHAN | Cholera Antitoxin, Goat. WHO International Standard |
CHS | Anti-Canine Hepatitis Serum |
COT | Clostridium novyi (alpha) Toxoid. WHO Reference Reagent |
CWBETATD | Clostridium Welchii (Perfringens)(Beta) Toxoid CwBT WHO Reference Reagent |
CWEPSILTD | Clostridium Welchii (Perfringens)( Epsilon) Toxoid CwDT WHO Reference Reagent |
DY | Anti-Dysentery (shiga) serum, Equine. WHO International Standard |
JNIH-11 | Bordela pertussis anti FHA serum (mouse) |
JNIH-12 | Bordela pertussis PT( LPF) anti serum, (mouse) |
JNIH-3 | Acellular Pertussis Vaccine - 1st IS. |
JNIH-4 | Bordela pertussis filamentous haemagglutinin (FHA) |
JNIH-5 | Bordela pertussis toxin (PT) 1st IS |
MEF/001 | Primary Mouse Embryo Fibroblasts (p0) |
MGDS | Anti-Mycoplasma gallisepticum Serum. WHO Reference Reagent |
NDS | Anti-Newcastle Disease Serum. WHO International Standard |
NVIA | Newcastle Disease Vaccine (Inactivated) WHO International Standard |
OE | Gas Gangrene Antitoxin (Cl. novyi), Equine WHO International Standard |
PE | Gas Gangrene Antitoxin (Cl. Perfringens alpha antitoxin) Equine WHO International Standard |
PPDA | Purified Protein Derivative (PPD) of M Avium Tuberculin WHO International Standard |
PPDBOV | Purified Protein Derivative (PPD) of Bovine Tuberculin WHO International Standard |
PPDT | Purified Protein Derivative (PPD) of M. Tuberculosis Tuberculin WHO International Standard |
QF | Anti-Q Fever Serum, Bovine WHO International Standard |
RBT/16 | Thromboplastin, Rabbit, Plain 5th International Standard 2016. |
RTF/16 | Thromboplastin, Human, Recombinant, Plain 5th International Standard 2016. |
RUBI-1-94 | Anti-rubella Immunoglobulin, Human WHO International Standard |
SES | Swine Erysipelas Serum (anti-N) WHO Reference Reagent |
SFS | Anti-Swine Fever Serum WHO International Standard |
SMV | Smallpox Vaccine WHO International Standard |
SPDS-S2 | Anti-Salmonella Pullorum Serum (Std. Form S) WHO International Standard |
SPDS-V | Anti-Salmonella Pullorum Serum (Variant Form V) WHO International Standard |
SPLS | Anti-Staphylococcal P-V Leucocidin serum, Equine WHO Reference Reagent |
SS-319/20 | FITC CD4 Positive Control Cells |
SSCLOT4 | SSC/ISTH Secondary Coagulation Standard Lot#4 |
STA | Staphylococcus Alpha Antitoxin, Equine WHO International Standard |
STT | Diphtheria (Schick) Test Toxin WHO International Standard |
TE-3 | Tetanus Immunoglobulin, Human WHO International Standard |
TILI | Anti-tick borne encephalitis serum (Louping Ill) WHO International Standard |
TISA | Anti-tick borne encephalitis serum (Sophyn & Absettarov) WHO International Standard |
TYVK | Typhoid Vaccine (acetone-inactivated) WHO International Standard |
TYVL | Typhoid Vaccine (heat-phenol-inactivated) WHO International Standard |
VI | Gas Gangrene Antitoxin (Cl. Septicum), Equine WHO International Standard |
W1004 | Anti-C complete blood typing serum,human WHO International Standard |
W1005 | Anti-E complete blood typing serum, human WHO International Standard |
W1007 | Anti-c Incomplete blood typing serum, human WHO International Standard |
W1044 | Anti-Varicella zoster immunoglobulin WHO International Standard |
W1062 | Anti smooth muscle(anti actin) autoantibody. WHO Reference Reagent |
W1063 | Anti nuclear ribonucleoprotein(nRNP) autoantibody WHO Reference Reagent |
W1064 | Anti-Nuclear factor serum,homogenous(66/233) |
W1066 | Rheumatoid Arthritis serum. WHO Reference Reagent |
YF | Anti-Yellow Fever Serum, monkey WHO Reference Reagent |
請輸入賬號
請輸入密碼
請輸驗證碼
以上信息由企業(yè)自行提供,信息內(nèi)容的真實性、準(zhǔn)確性和合法性由相關(guān)企業(yè)負責(zé),化工儀器網(wǎng)對此不承擔(dān)任何保證責(zé)任。
溫馨提示:為規(guī)避購買風(fēng)險,建議您在購買產(chǎn)品前務(wù)必確認供應(yīng)商資質(zhì)及產(chǎn)品質(zhì)量。